A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice (SURE NETHERLANDS)

NCT03929679 · Completed

Last updated 2026-05-28

This study is testing how the medication semaglutide affects blood sugar levels in adults with type 2 diabetes in the Netherlands as part of their regular medical care.

Status Completed The study has finished.

Type Observational

Participants 218 people

Who can join Ages 18+ · all sexes

Timeline Started 2019-05 · est. completion 2020-11

Where 27 sites · Netherlands

What this study is testing ClinicalTrials.gov NCT03929679 ↗

Description as written by the study sponsor.

The purpose of the study is to collect information on how semaglutide works in real world patients. Participants will get semaglutide prescribed by their study doctor. The study will last for about 6 to 8 months. The participants will be asked to complete some questionnaires about their health and their diabetes treatment. Participants will complete these during their normally scheduled visits with their study doctor.

Treatments tested

semaglutide Drug

Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.

Main thing measured	Change in Glycated Haemoglobin A1c (HbA1c)
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03929679 ↗